It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
IBT’s principals Dr. M. Javad Aman and Dr. Kelly Warfield have a long track record of scientific and developmental accomplishments in the filovirus field including highly productive work during their tenures at USAMRIID.
Dr. M. Javad Aman – President and CSO of Integrated BioTherapeutics, Inc.
Dr. M. Javad Aman received his Ph.D. in molecular immunology at the University of Mainz, Germany. He worked as a lead scientist at USAMRIID for 7 years prior to founding Integrated BioTherapeutics (IBT). His research at USAMRIID resulted in development of a vaccine for Ebola and Marburg viruses, now in late pre-clinical development.
Aman is the co-founder of Integrated BioTherapeutics, or IBT, in Gaithersburg, MD. IBT has developed an Ebola vaccine that, like the vaccines against HPV (human papillomavirus), uses “virus-like particles,” or VLPs. VLPs are like a sheep in wolf’s clothing. They contain proteins found on the surface of a virus, evoking an immune response, but they lack viral genetic material, so they can’t make people sick. The IBT vaccine is intended to protect wild gorillas and chimpanzees, for which Ebola is now considered as big a threat as poaching and habitat loss, according to the company.
In May, Aman and his collaborators published the results of a test of their Ebola vaccine in captive chimpanzees. The study found the vaccine triggered an immune response.
Last week, in what may be the biggest medical breakthrough of its kind in years, a group of scientists published results in The Lancet describing a completely new type of anti-viral treatment that appears to cure Ebola. They report a 100% success rate, although admittedly the test group was very small, just 4 rhesus monkeys. - See more at: genome.fieldofscience.com...
edit on 12-10-2014 by Mianeye because: (no reason given)
A reader has since asked for an update on the status of two RNA-based therapeutics – AVI-7288 and AVI-7537 – that had been in development by Sarepta Therapeutics for Marburg and Ebola viruses, respectively.
In July 2010, Sarepta had received a U.S. Department of Defense contract from the Joint Project Manager Transformational Medical Technologies Office (JPM-TMT) for these two phosphoramidate morpholino oligomers (PMOs) that were modifed to penetrate cells and resist metabolism.
For reasons that remain unclear today, the DoD discontinued the Ebola part of the contract with Sarepta in October 2012 and never reactivated it. The company is continuing to develop the oligomer against Marburg. We’ve contacted Sarepta for an update.
Question is have it been tested on humans and what was the result, there is a difference between "curing" 4 monkeys to "curing" humans, also the people working close to the infected would or should know about this.
originally posted by: pointr97
I'm not discrediting this by any stretch, but the download is obviously a presentation document........I'd love to see the narrative that goes with these slides, as there has to be a lot of meat that isn't presented in the slides.....but good find.